Provence Technologies launches US$1.7m research programme
Screening 1000 project aims to find and market a new ultra-pure molecule
Provence Technologies, a French research laboratory specialising in fine chemistry, has launched Screening 1000, a research programme with the goal of discovering a new ultra-pure molecule for the healthcare market.
Provence Technologies’ R&D department will run the two-year US$1.7m (€1.3m) project, which is being co-financed equally by Oseo, the French innovation promotion agency, and Marseille-based Provence Technologies.
Screening 1000 will first analyse 1,000 chemical compounds already on the market and detect those that show anomalies in purity. Provence Technologies will then focus on new compounds with the most promising market potential. To help achieve this, the company says it will develop new approaches to purification and synthesis to meet the purity levels required by health regulations.
‘The really innovative part of this program is implementing new solutions in the fields of purification of active principles or alternative synthesis pathways,’ said Claude Monteils, internal R&D project coordinator, Provence Technologies.’
As well as providing R&D services in the field of fine chemistry, Provence Technologies will continue to develop its own internal research projects and proprietary research efforts.
